Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.

Original languageEnglish (US)
Pages (from-to)7-14
Number of pages8
JournalCurrent Heart Failure Reports
Volume12
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Natriuretic Peptides
Heart Failure
Therapeutics
Manuscripts
Diuretics
Vasodilation
Homeostasis
Health
Morbidity
Mortality

Keywords

  • Cyclic guanosine monophosphate (cGMP)
  • Heart failure
  • Natriuretic peptide
  • Neprilysin
  • Neutral endopeptidase
  • Preclinical

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine
  • Medicine(all)

Cite this

@article{2776224754774565a2c27a3110749790,
title = "Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure",
abstract = "The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.",
keywords = "Cyclic guanosine monophosphate (cGMP), Heart failure, Natriuretic peptide, Neprilysin, Neutral endopeptidase, Preclinical",
author = "Paul McKie and Burnett, {John C Jr.}",
year = "2015",
doi = "10.1007/s11897-014-0235-3",
language = "English (US)",
volume = "12",
pages = "7--14",
journal = "PLoS Medicine",
issn = "1549-1277",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure

AU - McKie, Paul

AU - Burnett, John C Jr.

PY - 2015

Y1 - 2015

N2 - The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.

AB - The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.

KW - Cyclic guanosine monophosphate (cGMP)

KW - Heart failure

KW - Natriuretic peptide

KW - Neprilysin

KW - Neutral endopeptidase

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=84936775156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936775156&partnerID=8YFLogxK

U2 - 10.1007/s11897-014-0235-3

DO - 10.1007/s11897-014-0235-3

M3 - Article

C2 - 25331110

AN - SCOPUS:84936775156

VL - 12

SP - 7

EP - 14

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 1

ER -